Inventor · disambiguated record
Harald Duerr
Also filed as: DUERR HARALD
13 granted patents·16 pending applications·87 citations·filing 2011–2025
90Inventor score
Top patents by PatentIndex Score
29 records- 0197US9695233B2Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseasesROCHE GLYCART AG·Filed 2013·Granted Jul 4, 2017·44 cites·11 claims
- 0295US10941205B2Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2018·Granted Mar 9, 2021·10 cites·13 claims
- 0393US11242396B2Bispecific antigen binding molecules comprising anti-FAP clone 212HOFFMANN LA ROCHE·Filed 2019·Granted Feb 8, 2022·14 cites·36 claims
- 0491US11603411B2Bispecific anti-human CD20/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2018·Granted Mar 14, 2023·9 cites·5 claims
- 0591US10683345B2Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseasesROCHE GLYCART AG·Filed 2017·Granted Jun 16, 2020·5 cites·16 claims
- 0690US12030952B2Bispecific anti-human CD20/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2022·Granted Jul 9, 2024·1 cites·10 claims
- 0788US11787868B2Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2020·Granted Oct 17, 2023·1 cites·5 claims
- 0885US2025297025A1Bispecific anti-human a-beta/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2025·Application pending·0 cites
- 0983US2023365702A1Bispecific anti-human a-beta/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 1082US11780919B2Bispecific antigen binding molecules targeting OX40 and FAPHOFFMANN LA ROCHE·Filed 2021·Granted Oct 10, 2023·1 cites·24 claims
- 1182US2024317879A1Bispecific anti-human cd20/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 1281US12358997B1Bispecific anti-human A-beta/anti-human transferrin receptor antibodiesHOFFMANN LA ROCHE·Filed 2025·Granted Jul 15, 2025·0 cites·2 claims
- 1380US2023212277A1Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseasesHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 1478US2025179205A1Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fapHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 1576US10106600B2Bispecific antibodiesBRINKMANN ULRICH·Filed 2011·Granted Oct 23, 2018·2 cites·11 claims
- 1673US12275794B2Bispecific antigen binding molecules comprising anti-FAP clone 212HOFFMANN LA ROCHE·Filed 2021·Granted Apr 15, 2025·0 cites·27 claims
- 1773US2024117049A1Bispecific antigen binding molecules targeting ox40 and fapHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 1870US2025320305A1Bispecific antigen binding molecules comprising anti-fap clone 212HOFFMANN LA ROCHE·Filed 2025·Application pending·0 cites
- 1969US2021095013A1Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseasesROCHE GLYCART AG·Filed 2020·Application pending·0 cites
- 2067US12145994B2Bispecific antigen binding molecules capable of specific binding to CD40 and to fapHOFFMANN LA ROCHE·Filed 2021·Granted Nov 19, 2024·0 cites·17 claims
- 2165US2024376205A1Targeted interferon alpha fusion proteins and methods of useHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 2265US2020216554A1Bispecific anti-human cd20/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 2364US2025034269A1Agonistic ltbr antibodies and bispecific antibodies comprising themHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 2456US2018340030A1Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fapHOFFMANN LA ROCHE·Filed 2018·Application pending·0 cites
- 2552US2021292426A1Bispecific antigen binding molecules with trivalent binding to cd40HOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 2652US2020347115A1Novel tnf family ligand trimer-containing antigen binding moleculesHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 2750US2022162295A1Method for the expression of an antibody-multimer-fusionHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 2848US2025361279A1New Interleukin-7 ImmunoconjugatesHOFFMANN LA ROCHE·Filed 2025·Application pending·0 cites
- 2933US10316059B2Separation of bispecific antibodies and bispecific antibody production side products using hydroxyapatite chromatographyHOFFMANN LA ROCHE·Filed 2016·Granted Jun 11, 2019·0 cites·11 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →